4//SEC Filing
OXFORD BIOSCIENCE PARTNERS IV LP 4
Accession 0001181431-04-031292
CIK 0000761237other
Filed
Jun 16, 8:00 PM ET
Accepted
Jun 17, 5:47 PM ET
Size
14.7 KB
Accession
0001181431-04-031292
Insider Transaction Report
Form 4
OXFORD BIOSCIENCE PARTNERS IV LP
10% Owner
Transactions
- Purchase
Warrants to Purchase Common Stock
2004-04-14+1,452,098→ 1,452,098 totalExercise: $1.00From: 2004-04-14Exp: 2009-04-14→ Common Stock (1,452,098 underlying) - Purchase
Common Stock
2004-04-14$0.75/sh+2,904,195$2,178,146→ 9,321,292 total - Sale
Secured Promissory Notes
2004-04-19$0.75/sh−8,696,547.89$6,522,411→ 0 total - Purchase
Common Stock
2004-04-19$0.75/sh+11,595,397$8,696,548→ 26,065,491 total - Purchase
Common Stock
2004-04-14$0.75/sh+5,148,802$3,861,602→ 14,470,094 total - Sale
Revolving Convertible Senior Secured Promissory Notes
2004-04-14$0.75/sh−3,861,601.5$2,896,201→ 0 total
Footnotes (4)
- [F1]On April 14, 2004, the reporting person agreed to purchase 2,904,195 shares of common stock, 568,678 shares were issued at the initial closing on April 19, 2004 and an additional 2,335,517 shares will be issued at the second closing to occur no later than July 19, 2004.
- [F2]On April 14, 2004, the reporting person agreed to convert convertible notes in the aggregate amount of $3,861,601.50, including the principal amount of $3,623,644 and interest of $237,957.50, at a conversion price of $0.75 per share, which resulted in the acquisition of 5,148,802 shares of common stock. The convertible notes were convertible into common stock at a conversion price equal to the price of the common stock in a qualified equity financing at the same price on the same terms as securities sold to investors in such qualified equity financing.
- [F3]On April 19, 2004, the reporting person agreed to convert secured notes in the aggregate amount of $8,696,547.89, including the principal amount of $8,239,373.33 and interest in an amount of approximately $457,174.56, at a conversion price of $0.75 per share. The closing of the conversion of secured notes will occur no later than July 19, 2004. The conversion of the principal amount of notes will result in the acquisition of 10,985,831 shares of common stock and the conversion of the interest amount will result in the acquisition of approximately 609,566 shares of common stock. The notes became convertible pursuant to a security purchase agreement entered into on April 19, 2004.
- [F4]On April 14, 2004, the reporting person agreed to purchase warrants to purchase 1,452,098 shares of common stock, warrants to purchase 284,339 shares of common stock were issued at the initial closing on April 19, 2004 and warrants to purchase an additional 1,167,759 shares will be issued at the second closing to occur no later than July 19, 2004.
Documents
Issuer
IMCOR PHARMACEUTICAL CO
CIK 0000761237
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001140484
Filing Metadata
- Form type
- 4
- Filed
- Jun 16, 8:00 PM ET
- Accepted
- Jun 17, 5:47 PM ET
- Size
- 14.7 KB